S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
NASDAQ:MASI

Masimo (MASI) Stock Price, News & Analysis

$134.77
-1.15 (-0.85%)
(As of 04:00 PM ET)
Today's Range
$133.64
$137.44
50-Day Range
$126.49
$146.85
52-Week Range
$75.22
$198.00
Volume
341,165 shs
Average Volume
576,822 shs
Market Capitalization
$7.13 billion
P/E Ratio
89.25
Dividend Yield
N/A
Price Target
$137.43

Masimo MarketRank™ Stock Analysis

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
1.9% Upside
$137.43 Price Target
Short Interest
Healthy
8.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.71mentions of Masimo in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.83%
From $3.51 to $3.82 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.05 out of 5 stars

Medical Sector

165th out of 918 stocks

Electromedical Equipment Industry

3rd out of 19 stocks

MASI stock logo

About Masimo Stock (NASDAQ:MASI)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

MASI Stock Price History

MASI Stock News Headlines

Masimo (NASDAQ:MASI) Shares Gap Up to $137.92
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Masimo (NASDAQ:MASI) Upgraded to Buy at Stifel Nicolaus
Stifel Upgrades Masimo (MASI)
Forecasting The Future: 6 Analyst Projections For Masimo
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Masimo CEO: Politan wants to oust me
Company News for Mar 26, 2024
Analyst Scoreboard: 5 Ratings For Masimo
See More Headlines
Receive MASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Masimo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/19/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:MASI
CUSIP
57479510
Employees
5,200
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$137.43
High Stock Price Target
$170.00
Low Stock Price Target
$86.00
Potential Upside/Downside
+2.4%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$81.50 million
Pretax Margin
4.30%

Debt

Sales & Book Value

Annual Sales
$2.05 billion
Cash Flow
$5.66 per share
Book Value
$25.79 per share

Miscellaneous

Free Float
47,780,000
Market Cap
$7.10 billion
Optionable
Optionable
Beta
0.97

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

MASI Stock Analysis - Frequently Asked Questions

Should I buy or sell Masimo stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MASI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MASI, but not buy additional shares or sell existing shares.
View MASI analyst ratings
or view top-rated stocks.

What is Masimo's stock price target for 2024?

7 Wall Street research analysts have issued 1 year price targets for Masimo's shares. Their MASI share price targets range from $86.00 to $170.00. On average, they predict the company's share price to reach $137.43 in the next twelve months. This suggests a possible upside of 1.9% from the stock's current price.
View analysts price targets for MASI
or view top-rated stocks among Wall Street analysts.

How have MASI shares performed in 2024?

Masimo's stock was trading at $117.21 at the beginning of 2024. Since then, MASI stock has increased by 15.1% and is now trading at $134.86.
View the best growth stocks for 2024 here
.

When is Masimo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MASI earnings forecast
.

How were Masimo's earnings last quarter?

Masimo Co. (NASDAQ:MASI) posted its quarterly earnings data on Tuesday, February, 27th. The medical equipment provider reported $1.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.82 by $0.43. The medical equipment provider earned $548.90 million during the quarter, compared to analysts' expectations of $545.69 million. Masimo had a net margin of 3.98% and a trailing twelve-month return on equity of 13.77%. The business's revenue for the quarter was down 11.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.32 EPS.

What guidance has Masimo issued on next quarter's earnings?

Masimo updated its FY 2024 earnings guidance on Friday, April, 19th. The company provided earnings per share (EPS) guidance of 3.440-3.600 for the period, compared to the consensus earnings per share estimate of 3.520. The company issued revenue guidance of $2.0 billion-$2.2 billion, compared to the consensus revenue estimate of $2.1 billion.

What is Joe E. Kiani's approval rating as Masimo's CEO?

136 employees have rated Masimo Chief Executive Officer Joe E. Kiani on Glassdoor.com. Joe E. Kiani has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Masimo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Netflix (NFLX), Shopify (SHOP), Okta (OKTA), PayPal (PYPL), Alibaba Group (BABA), Mastercard (MA), Trade Desk (TTD), Walt Disney (DIS) and Twilio (TWLO).

Who are Masimo's major shareholders?

Masimo's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.74%), Allspring Global Investments Holdings LLC (0.09%), Cardinal Capital Management (0.03%), State of Michigan Retirement System (0.02%), Handelsinvest Investeringsforvaltning (0.00%) and Juncture Wealth Strategies LLC (0.00%). Insiders that own company stock include Adam Mikkelson, Joe E Kiani, Micah W Young and Tao Levy.
View institutional ownership trends
.

How do I buy shares of Masimo?

Shares of MASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MASI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners